UBS’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
Sell
-117,100
Closed -$2.82M 11315
2014
Q2
$2.82M Buy
117,100
+116,900
+58,450% +$1.22M ﹤0.01% 2542
2014
Q1
$1K Sell
200
-35,000
-99% -$244K ﹤0.01% 10320
2013
Q4
$211K Buy
35,200
+26,400
+300% +$122K ﹤0.01% 5248
2013
Q3
$46K Buy
8,800
+6,300
+252% +$27.6K ﹤0.01% 6991
2013
Q2
$9K Buy
+2,500
New +$10.2K ﹤0.01% 8790

UBS's IDIX Position: Q3 2014 in Review

UBS sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q3 2014, closing a stake of 80,677 shares — an estimated $1.94M sold.

UBS first reported a position in IDIX in Q2 2013 and held it in 5 quarters. The position peaked at $2.13M in Q2 2013. 0 funds tracked by Wall St. Rank hold IDIX as of Q3 2014.

  • UBS reported no remaining IDENIX PHARMACEUTICALS INC position as of Q3 2014 after selling out during the quarter.
  • UBS sold 80,677 IDENIX PHARMACEUTICALS INC shares in Q3 2014, an estimated $1.94M.
  • UBS first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 5 quarters.
  • UBS's IDENIX PHARMACEUTICALS INC position peaked at $2.13M in Q2 2013.
  • 0 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.